EU biotech law should have high level of data protection, regulators say
MLex Summary: The EU's planned biotech law should not lower the level of data protection for clinical trial participants, two EU data protection bodies have said. In a joint statement, the...To view the full article, register now.
Already a subscriber? Click here to view full article